Earnings call transcript: AngioDynamics Q3 2026 beats EPS forecast, shares dip

AngioDynamics beat Q3 expectations with EPS of -$0.07 vs. -$0.09 consensus (22.2% surprise) and revenue of $78.4M, up 8.9% YoY and ~2.2% above forecasts; adjusted EBITDA rose to $1.8M (+38.5% YoY). Management raised FY2026 net sales guidance to $313.5–$315.5M and adjusted EBITDA to $10–$12M, but gross margin compressed to 52.9% from 63.0% (-1,010 bps) due largely to a $1.3M Q3 tariff hit and ongoing manufacturing transition (tariff exposure $4–$6M expected FY), and the stock traded down ~2.85% pre-market at $11.60 (market cap ~$492M). MedTech momentum (MedTech +19% and now 48% of revenue) underpins upside (analyst targets $16–$24), but continued unprofitability, tariff/manufacturing costs and sterilization/supply risks are key downside risks.

Analysis

AngioDynamics sits at the inflection where boutique MedTech product adoption (consumable-heavy platforms) can meaningfully re-rate a previously device-centric business. The commercial cadence — approval into hospital formularies and higher utilization per account — implies recurring revenue growth that compounds faster than one-off capital sales, creating a multi-quarter lever where margin expansion can lag revenue inflections by 2-4 quarters due to inventory and sterilization timing.

Tariff and supply-chain noise is acting like a temporary tax on earnings rather than a structural demand shock; that makes near-term cash and margin volatility predictable and hedgeable. The company’s manufacturing footprint shift and planned inventory pre-build ahead of vendor maintenance are second-order positives for continuity but will pull forward cash usage, concentrating downside risk into a short window while preserving medium-term gross margin tailwinds once transition completes.

The largest asymmetric is optionality from procedure-adjacent ecosystems — device platforms that create reusable capital plus recurring disposables (e.g., thrombectomy and ablation probes) can generate durable annuity-style revenue if clinical/regulatory and reimbursement pathways continue. Execution risks cluster around management transition and sterilization capacity; a stumble there would compress multiples quickly, making patient-monitoring of weekly procedure metrics and sterilizer uptime high-value signals for traders.

Key Decisions for Investors

• Long ANGO equity (12–18 month horizon): Conviction trade to capture procedural adoption + consumable pull-through. Initiate on any >10% intraday pullback; target +40–60% total return, stop -30% (execution risk tied to leadership transition and sterilization disruptions).
• Call-spread (event-driven): Buy ANGO Jan 2027 15/25 call spread (cost-limited way to own adoption upside ahead of FY27 procedure acceleration). Risk: premium lost if adoption/gross-margin noise persists; reward asymmetry >2x if market re-rates on sequential share gains.
• Relative-value pair: Long ANGO / short MDT (or IHI ETF) over 9–12 months to isolate MedTech growth capture vs. large-cap slow-growth incumbents. Size to target a portfolio-level 15–20% directional exposure; unwind if ANGO misses two consecutive quarterly utilization metrics or if hospital VAC approvals stall.
• Tactical hedge: Buy short-dated puts or a protective collar ahead of key sterilizer-maintenance windows and any near-term management announcements (30–90 day horizon). This caps downside from concentrated cash/inventory flows and reduces gamma risk around scheduled vendor maintenance.